Samsara Therapeutics

Biotechnology company with laboratories at Oxford and offices in the United States, founded in 2018 on academic work in autophagy, the process by which cells clear damaged material. Screens and develops small molecules that switch autophagy on, aiming at neurodegenerative and age related disease, and works with academic groups and investors on preclinical candidates.